Alfred L. Garfall, MD, emphasizes the critical importance of the National Institutes of Health funding for biomedical research.
The FDA has approved 2 biosimilars, denosumab-bmwo (CT-P41; Stoboclo) and (Osenvelt), for all indications of their respective reference products (Prolia) and (Xgeva), Celtrion stated in a news release ...
Tislelizumab plus chemotherapy is now FDA-approved for metastatic esophageal squamous cell carcinoma with a tumor PD-L1 ...
David Zhen, MD, discussed the relevance of nivolumab in the upper gastrointestinal cancer population. In an interview with ...
Alejandro Rios Hoyo discussed findings on a subset of hormone receptor–positive, HER2-negative breast cancers classified as ...
Uday R. Popat, MD, discusses the rationale behind evaluating itacitinib over other JAK inhibitors for graft-vs-host disease prophylaxis in a phase 2 study.
Palak Dave discusses the potential role of artificial intelligence in improving the accuracy of myelodysplastic syndromes ...
Rusfertide outperformed placebo in polycythemia vera, meeting all primary and secondary end points in the phase 3 VERIFY ...
A panelist discusses how a patient’s initial presentation and molecular profile guide personalized treatment approaches for ...
A panelist discusses how a 67-year-old male smoker presented with frequent headache and dizziness but had an otherwise unremarkable medical history with no splenomegaly.
Matthew Matasar, MD, discusses odronextamab and the ongoing phase 1 ELM-1 trial in patients with CD20-positive B-cell malignancies.
The FDA advances in multiple cancer types, and researchers assess potential impacts of funding freezes on cancer research.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback